Loading clinical trials...
Loading clinical trials...
At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB) Amendment 7, Part B Sub Study: The primary ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bristol-Myers Squibb
NCT07024641 · Hepatitis B Virus Infection
NCT05856890 · Hepatitis b Virus, Hepatitis B
NCT07275554 · HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis, and more
NCT06906016 · Chronic Hepatitis B Virus (HBV) Infection
NCT06881238 · Inflammatory Bowel Disease (IBD), Hepatitis B Virus
Advanced Clinical Research Institute
Anaheim, California
Sc Clinical Research, Inc.
Garden Grove, California
University Of California, Davis Medical Center
Sacramento, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions